Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma

PURPOSE: Combining immunotherapeutic agents with different mechanisms of action may enhance efficacy. We describe the safety and efficacy of talimogene laherparepvec (T-VEC; an oncolytic virus) in combination with ipilimumab (a cytotoxic T-lymphocyte–associated antigen 4 checkpoint inhibitor) in pat...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Puzanov, Igor, Milhem, Mohammed M., Minor, David, Hamid, Omid, Li, Ai, Chen, Lisa, Chastain, Michael, Gorski, Kevin S., Anderson, Abraham, Chou, Jeffrey, Kaufman, Howard L., Andtbacka, Robert H.I.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2016
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7189507/
https://ncbi.nlm.nih.gov/pubmed/27298410
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2016.67.1529
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados